Clinical trials: Aicardi-Goutières Syndrome (AGS)
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM)
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
The Requesting Physician/Investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
- Conditions
- Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)
- Trial name
- NCT01724580
- Testing
- Baricitinib
- Where
- 3 sites in United States, United Kingdom
- Sponsor
- Eli Lilly and Company
Aicardi-Goutières Syndrome (AGS)
Reverse Transcriptase Inhibitors in AGS
The purpose of this study is to determine if treatment with reverse transcriptase inhibitors returns the interferon signature observed in patients with AGS to normal levels.
- Trial name
- RTIs in AGS (NCT02363452)
- Testing
- Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Aicardi-Goutières Syndrome (AGS)
Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome
Aicardi-Goutières Syndrome (AGS) is a hereditary multisystem autoinflammatory disorder that predominantly affects the central nervous system.
- Trial name
- NCT06898372
- Testing
- JAK Inhibitor
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- IRCCS Fondazione Stella Maris
Aicardi Goutieres Syndrome
JAK Inhibitor Treatment in AGS
The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate…
- Trial name
- NCT03921554
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Adeline Vanderver, MD
Aicardi-Goutières Syndrome (AGS)
TPN-101 in Aicardi-Goutières Syndrome (AGS)
A phase 2a multi-center, open-label single dose level study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)
- Trial name
- NCT05613868
- Testing
- TPN-101
- Where
- 5 sites in France, Italy and 1 more
- Volunteers
- 4 people
- Sponsor
- Transposon Therapeutics, Inc.